Distinct plasma immune signatures in ME/CFS are present early in the course of illness - Test2 - elhamkhani - TriplyDB

Distinct plasma immune signatures in ME/CFS are present early in the course of illness

Distinct plasma immune signatures in ME/CFS are present early in the course of illness

http://www.wikidata.org/entity/Q28263550

about

Myalgic Encephalomyelitis: Symptoms and Biomarkers Illness progression in chronic fatigue syndrome: a shifting immune baseline The biological challenge of myalgic encephalomyelitis/chronic fatigue syndrome: a solvable problem From good health to illness with post-infectious fatigue syndrome: a qualitative study of adults' experiences of the illness trajectory.Abnormal Resting-State Functional Connectivity in Patients with Chronic Fatigue Syndrome: Results of Seed and Data-Driven Analyses.Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome Examining clinical similarities between myalgic encephalomyelitis/chronic fatigue syndrome and D-lactic acidosis: a systematic review Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment Sleep quality and the treatment of intestinal microbiota imbalance in Chronic Fatigue Syndrome: A pilot study Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome.Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome.A Pair of Identical Twins Discordant for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Differ in Physiological Parameters and Gut Microbiome Composition.Fibromyalgia syndrome in need of effective treatments.Serum Immune Proteins in Moderate and Severe Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients.Mitochondrial DNA variants correlate with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome.Replacing Myalgic Encephalomyelitis and Chronic Fatigue Syndrome with Systemic Exercise Intolerance Disease Is Not the Way forward The Relationship between Age and Illness Duration in Chronic Fatigue Syndrome Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines Interleukin-1 as a mediator of fatigue in disease: a narrative review.Review of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: an evidence-based approach to diagnosis and management by clinicians.Cytokine signature associated with disease severity in chronic fatigue syndrome patients.Telephone-administered versus live group cognitive behavioral stress management for adults with CFS.RNA-Seq Analysis of Gene Expression, Viral Pathogen, and B-Cell/T-Cell Receptor Signatures in Complex Chronic Disease.Association of mitochondrial DNA variants with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) symptoms.Mechanisms Explaining Muscle Fatigue and Muscle Pain in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a Review of Recent Findings.Immune network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome with atypical and classical presentations.Reversal of Refractory Ulcerative Colitis and Severe Chronic Fatigue Syndrome Symptoms Arising from Immune Disturbance in an HLA-DR/DQ Genetically Susceptible Individual with Multiple Biotoxin Exposures.Cytokine signatures in chronic fatigue syndrome patients: a Case Control Study and the effect of anakinra treatment.Cytokine responses to exercise and activity in patients with chronic fatigue syndrome: case-control study.Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis/chronic fatigue syndrome: neuropsychological symptoms and sex comparisons.Value of Circulating Cytokine Profiling During Submaximal Exercise Testing in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.A Molecular Neurobiological Approach to Understanding the Aetiology of Chronic Fatigue Syndrome (Myalgic Encephalomyelitis or Systemic Exertion Intolerance Disease) with Treatment Implications.Inflammation correlates with symptoms in chronic fatigue syndrome.Infection Elicited Autoimmunity and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: An Explanatory Model.Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study.Association of chronic fatigue syndrome with premature telomere attrition.Weighting of orthostatic intolerance time measurements with standing difficulty score stratifies ME/CFS symptom severity and analyte detection.Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

P2860

Q26786545-4B3EC071-68E3-465D-9D2D-FF4031EF4B02 Q28389279-4C6DF2FB-9B5B-4F52-AEAC-8CB3B32200CA Q28394255-84E399DF-85C3-4B5C-B9CD-9A586EEB35BF Q30843149-3B14C29A-D217-48BF-8F25-0503D34F631E Q31003423-32535712-5D9E-4B2A-9CC6-F0C7F61DCD2E Q33604317-855F4E17-4A09-4F7A-B419-79F61236E811 Q33776463-F2871E77-E5E0-44BC-9B52-8BA10750B2D5 Q34161527-6A416CCD-A7B0-42A5-93AD-77D04906B59B Q34520840-63CE9DB0-88D0-48A3-968E-2DA155C4BF13 Q35680023-764DF9FE-2A46-453E-B4C8-BBF36AEC4946 Q35896707-B4827664-0E4D-407D-9223-0F5C29A70C4D Q36060516-EE36540D-41D8-4955-A6D9-1EA310440625 Q36106681-AED15D59-6B92-4788-A0AD-1AD6F47F01A9 Q36158720-20E0BAA3-2A1D-404F-9AAB-8FCBC889F75E Q36186172-9FF48861-D9DB-4763-AAB9-C037839CC756 Q36189738-3BA85794-D47E-41CC-804B-FECE74E6E6E9 Q36480750-AAE3A9DD-7654-4456-9C10-5C6A1D991B8B Q36731913-835BFF78-60C9-4B36-BE95-5A5919C35EA6 Q37061432-076C44F9-7C6E-4BDA-8EB4-B5D2ABB74DE2 Q37133826-AFDAAC8D-2257-43C7-891A-543BAB4803AC Q37597282-8325E704-0480-4D77-8AC6-347727B2D065 Q38650323-02E9AC59-464E-4BC7-8F13-A403FC5CD54C Q38650803-09BE7FEC-A8CD-49BC-AE25-0B26ADA004ED Q38767944-95D502DA-14A6-486B-9349-FEC4BCD51A48 Q38973903-AF980FAC-330B-481F-AB4C-6A7B9573B1EF Q39081948-EF6ED89A-7616-4E54-8CFF-E6EC7741F691 Q39100152-3BD63113-8495-4F6F-8C66-F6A7F373DA49 Q40259234-7D5C52FC-F4B8-4008-9C79-F6D60704B15A Q42054198-6FB15038-4DB0-4CAD-9101-A325F553BA5F Q47144415-E83DDBAF-0093-489B-9813-6121EDE59336 Q47988167-1357B9A2-BB8E-41A7-9AEB-CC3006A69027 Q48096334-0CF964F4-1A4F-4E1D-9B00-2FB08A822D7C Q49298029-D3BEC7DC-0A50-4757-AF5E-E3C0B474D254 Q50145916-20139884-0C97-48D2-8171-74BD95B0F642 Q50326870-2AC309D2-479E-4294-8356-C861963BB4D6 Q50333926-9A081900-1F6D-41AA-8BB5-EB088275CC06 Q50689763-0AC66E2E-6335-4249-97D4-DA0214EE0FA8 Q51766849-C598B142-ABDC-48E0-8C3D-4396F8BE8914 Q53412073-371E9B8C-8E15-4CD5-8D6D-CD0A8737123C Q55387468-B7B8E378-CFE2-4C9F-B1D0-334425D24E46

P2860

Distinct plasma immune signatures in ME/CFS are present early in the course of illness

http://www.wikidata.org/entity/Q28263550

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Distinct plasma immune signatures in ME/CFS are present early in the course of illness

@ast

Distinct plasma immune signatures in ME/CFS are present early in the course of illness

@en

Distinct plasma immune signatures in ME/CFS are present early in the course of illness

@nl

type

label

Distinct plasma immune signatures in ME/CFS are present early in the course of illness

@ast

Distinct plasma immune signatures in ME/CFS are present early in the course of illness

@en

Distinct plasma immune signatures in ME/CFS are present early in the course of illness

@nl

prefLabel

Distinct plasma immune signatures in ME/CFS are present early in the course of illness

@ast

Distinct plasma immune signatures in ME/CFS are present early in the course of illness

@en

Distinct plasma immune signatures in ME/CFS are present early in the course of illness

@nl

P1433

Q28263550-B4D6DB0F-EE31-46BF-817A-15CE315B3EEE

P1476

Q28263550-7A0401DC-F0E0-4BF6-BD21-F99FECB74446

P2093

Q28263550-097B060F-4B2C-43AC-8016-41283371D3F5

Q28263550-17041A23-5AE5-4883-9754-F0895DB6F3BD

Q28263550-271F1FAA-784D-404C-868C-A9EDBD2209F3

Q28263550-44019C08-A5F7-45A6-B9A0-B2562D0D8272

Q28263550-9B8DED19-C9E5-41B8-B02C-E9EFAE2DF50D

Q28263550-A97052FA-F3D9-42AF-BDEA-0BE7CB303A1F

Q28263550-C99F6157-6C11-486B-B075-1FE06F5831A5

Q28263550-DF88B401-00AA-4C86-AE9E-5DACC93D03C0

Q28263550-FA7C0228-D2DF-4D07-8A16-90D19FD8545C

P2860

Q28263550-0480E687-B2CD-4B1C-87D8-7DA475123F35

Q28263550-07D3C6B8-C54C-4EE7-A200-F6EC09748041

Q28263550-0F9723CB-BC44-47BD-9472-076E5B2DE531

Q28263550-1043FB38-04B3-427C-B35D-EE86273A27C4

Q28263550-1504B70A-1C91-495C-ACBE-2583DA5AAA1A

Q28263550-16EA71A0-CBC2-4CDE-9FC3-7BC724FD08FA

Q28263550-185F3630-D70A-4B7C-98AE-991892EC5735

Q28263550-19128858-7E28-49EF-B938-B728CCA1547A

Q28263550-19C0E588-E65D-48A2-9F5F-EF1E02277264

Q28263550-1A685FDF-595C-48B2-B5DA-63EC26DC196D

P304

Q28263550-154EC049-AAED-412B-8578-ACA109D58159

P31

Q28263550-FC8C9A3B-5467-4DA7-8B34-E14A395B6FD5

P3181

Q28263550-937CE2DF-6933-455B-AE5C-FA162206AC12

P356

Q28263550-38B3AECA-D813-43FB-B4E9-CC87780D8A3B

P407

Q28263550-EEE68D6B-FC21-40B6-B792-1327E45CED35

P433

Q28263550-0A4D23D7-A2D8-45CE-9F73-D285CEA90E83

P478

Q28263550-D5A3FB83-80AD-4A88-86A1-853FD033DD55

P50

Q28263550-2D3AF926-50E6-45C2-9BF0-2D4ED7C304E3

Q28263550-6C665C7F-ACE7-4362-9454-D07031998AEA

Q28263550-89C6239F-8BE4-45BE-8D74-6530C9FE8651

Q28263550-C2426A5D-E4C1-41CF-83E5-A3F2DD4C1159

P577

Q28263550-D6A54912-9035-41A1-92B1-A09C82204ACF

P698

Q28263550-B1D60F6B-19B6-49F9-84A4-669ECC252FB4

P932

Q28263550-37EA9159-4130-47F6-9631-2CB22055084E

P3181

P356

P1433

Science Advances

P1476

Distinct plasma immune signatures in ME/CFS are present early in the course of illness

@en

P2093

Andrew F Schultz

http://www.w3.org/2001/XMLSchema#string

Anthony L Komaroff

http://www.w3.org/2001/XMLSchema#string

C Gunnar Gottschalk

http://www.w3.org/2001/XMLSchema#string

Daniel L Peterson

http://www.w3.org/2001/XMLSchema#string

Donna Felsenstein

http://www.w3.org/2001/XMLSchema#string

José G Montoya

http://www.w3.org/2001/XMLSchema#string

Meredith L Eddy

http://www.w3.org/2001/XMLSchema#string

Susan Levine

http://www.w3.org/2001/XMLSchema#string

Xiaoyu Che

http://www.w3.org/2001/XMLSchema#string

P2860

Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study

Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): a systematic review

Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics

Upregulation of PD-1 Expression on Circulating and Intrahepatic Hepatitis C Virus-Specific CD8+ T Cells Associated with Reversible Immune Dysfunction

The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group

Regulation of interferon-gamma during innate and adaptive immune responses

The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations

Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis.

Multiplexed particle-based flow cytometric assays.

Interferon-gamma produced by microglia and the neuropeptide PACAP have opposite effects on the viability of neural progenitor cells.

P304

e1400121-e1400121

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

529377

http://www.w3.org/2001/XMLSchema#string

P356

10.1126/SCIADV.1400121

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Nancy G. Klimas

Lucinda Bateman

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26079000

http://www.w3.org/2001/XMLSchema#string

P932

4465185

http://www.w3.org/2001/XMLSchema#string